BRPI1016182A2 - método para o tratamento da leucemia mieloide aguda - Google Patents
método para o tratamento da leucemia mieloide agudaInfo
- Publication number
- BRPI1016182A2 BRPI1016182A2 BRPI1016182A BRPI1016182A BRPI1016182A2 BR PI1016182 A2 BRPI1016182 A2 BR PI1016182A2 BR PI1016182 A BRPI1016182 A BR PI1016182A BR PI1016182 A BRPI1016182 A BR PI1016182A BR PI1016182 A2 BRPI1016182 A2 BR PI1016182A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- myeloid leukemia
- acute myeloid
- acute
- leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09158496A EP2243833A1 (en) | 2009-04-22 | 2009-04-22 | Method for the treatment of acute myeloid leukemia |
| PCT/EP2010/055355 WO2010122109A1 (en) | 2009-04-22 | 2010-04-22 | Method for the treatment of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016182A2 true BRPI1016182A2 (pt) | 2019-09-24 |
Family
ID=40935648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016182A BRPI1016182A2 (pt) | 2009-04-22 | 2010-04-22 | método para o tratamento da leucemia mieloide aguda |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120088811A1 (pt) |
| EP (2) | EP2243833A1 (pt) |
| JP (1) | JP2012524758A (pt) |
| KR (1) | KR20110138414A (pt) |
| CN (1) | CN102421899A (pt) |
| BR (1) | BRPI1016182A2 (pt) |
| CA (1) | CA2759597A1 (pt) |
| EA (1) | EA201101531A1 (pt) |
| MX (1) | MX2011010610A (pt) |
| WO (1) | WO2010122109A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142313A2 (en) * | 2011-04-12 | 2012-10-18 | Beth Israel Deaconess Medical Center, Inc. | Micro-rna inhibitors and their uses in disease |
| JP6156621B2 (ja) * | 2012-02-14 | 2017-07-05 | 国立大学法人 岡山大学 | Atllの診断のためのデータ取得方法、atll診断用キットおよびatll診断システム |
| US20160208346A1 (en) * | 2013-08-19 | 2016-07-21 | Notre Dame Du Lac | Method and composition for detection of oncogenic hpv |
| US9822358B2 (en) | 2013-10-18 | 2017-11-21 | Beth Israel Deaconess Medical Center | Treatment of cancers with micro-RNA inhibitors |
| KR101476781B1 (ko) * | 2014-05-09 | 2014-12-29 | 충남대학교산학협력단 | 결핵 진단용 바이오마커 마이크로 rna |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CN106367474B (zh) * | 2015-07-21 | 2020-01-31 | 益善生物技术股份有限公司 | 18种miRNA检测探针和液相芯片 |
| BR112018016924A2 (pt) * | 2016-02-23 | 2019-01-02 | Biolinerx Ltd | método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma |
| CN114392346A (zh) * | 2022-01-19 | 2022-04-26 | 山东大学齐鲁医院 | 亨廷顿相互作用蛋白-1相关蛋白基因和/或其编码的蛋白的新应用 |
-
2009
- 2009-04-22 EP EP09158496A patent/EP2243833A1/en not_active Withdrawn
-
2010
- 2010-04-22 CN CN2010800177016A patent/CN102421899A/zh active Pending
- 2010-04-22 EA EA201101531A patent/EA201101531A1/ru unknown
- 2010-04-22 MX MX2011010610A patent/MX2011010610A/es not_active Application Discontinuation
- 2010-04-22 JP JP2012506504A patent/JP2012524758A/ja active Pending
- 2010-04-22 EP EP10717598A patent/EP2421968A1/en not_active Withdrawn
- 2010-04-22 BR BRPI1016182A patent/BRPI1016182A2/pt not_active IP Right Cessation
- 2010-04-22 US US13/138,914 patent/US20120088811A1/en not_active Abandoned
- 2010-04-22 WO PCT/EP2010/055355 patent/WO2010122109A1/en not_active Ceased
- 2010-04-22 KR KR1020117027663A patent/KR20110138414A/ko not_active Withdrawn
- 2010-04-22 CA CA2759597A patent/CA2759597A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2759597A1 (en) | 2010-10-28 |
| MX2011010610A (es) | 2012-01-30 |
| WO2010122109A9 (en) | 2011-02-17 |
| EP2243833A1 (en) | 2010-10-27 |
| EA201101531A1 (ru) | 2012-05-30 |
| WO2010122109A1 (en) | 2010-10-28 |
| EP2421968A1 (en) | 2012-02-29 |
| JP2012524758A (ja) | 2012-10-18 |
| US20120088811A1 (en) | 2012-04-12 |
| CN102421899A (zh) | 2012-04-18 |
| KR20110138414A (ko) | 2011-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0921482A2 (pt) | tratamento de leucemia linfoblástica aguda | |
| LTC2515855I2 (lt) | Suderinta terapija, skirta LOPL | |
| IL232222A0 (en) | Methods for treating progressive multiple sclerosis | |
| BRPI1016182A2 (pt) | método para o tratamento da leucemia mieloide aguda | |
| FI20075434L (fi) | Prosessi haaroittuneiden hiilivetyjen valmistamiseksi | |
| BRPI0921341A2 (pt) | tratamento de leucemia linfoblástica aguda pediátrica | |
| SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
| PL2349132T3 (pl) | Aparat do leczenia gerd | |
| BRPI0911923A2 (pt) | dispositivos filamentosos para o tratamento de defeitos vasculares | |
| CO6821964A2 (es) | Compuestos para el tratamiento de la adicción | |
| FI20075433L (fi) | Prosessi haaroittuneiden hiilivetyjen valmistamiseksi | |
| EP2627333A4 (en) | Combination treatment of cancer | |
| DK2452189T3 (da) | Fremgangsmåde til identifikation af forbindelser til behandling af cancer | |
| BRPI0922871A2 (pt) | metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI1007459A2 (pt) | método para produção de manômeros olefínicos | |
| BRPI1012237A2 (pt) | método para produção de hidrocarbonetos aromáticos | |
| EP2457154A4 (en) | MULTIPLEXING WITH PSEUDO-SYNCHRONOUS DISTRIBUTION IN TIME | |
| BRPI0922490A2 (pt) | Método para produção de beta-santaleno | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| BRPI1007391A2 (pt) | processo para o resfriamento controlado da troposfera | |
| DK2346661T3 (da) | Dannelsesfremgangsmåder | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
| DE112009002122A5 (de) | Beschichtungsverfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |